Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil

This study has been withdrawn prior to enrollment.
(we didnt recieved the medicine)
Information provided by:
The Baruch Padeh Medical Center, Poriya Identifier:
First received: September 24, 2008
Last updated: February 28, 2010
Last verified: July 2009
The investigators would like to study the endothelial function in sickle cell patients without pulmonary hypertension in an in vivo method during a steady state condition before and after sildenafil treatment for 1 month, and to study the effects of this nitric oxide donor by measuring the Flow Mediated Dilatation, by measuring endothelial progenitor stem cells colonies, and by measuring the effect of therapy on markers of inflammation (cell adhesion molecules and cytokines).

Condition Intervention Phase
Sickle Cell Anemia
Drug: Viagra (Sildenafil)
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Caregiver, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Primary Outcome Measures:
  • endothelial function before and after viagra treatment to patients with sickle cell anemia without pulmonary hypertension [ Time Frame: January 2009 till January 2011 ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: September 2009
Estimated Study Completion Date: February 2010
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: viagra
viagra versus placebo will be given to patients with sickle cell anemia
Drug: Viagra (Sildenafil)
Viagra treatment to patients with sickle cell anemia.
Placebo Comparator: placebo
viagra versus placebo will be given to patients with sickle cell anemia
Drug: placebo


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with sickle cell anemia

Exclusion Criteria:

  • patients with sickle cell anemia during acute crisis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00937144

Baruch Padeh Poria Medical Center
Tiberias, Lower Galilee, Israel, 15208
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
  More Information

Responsible Party: baruch padeh poria medical center, ministry of health, Israel Identifier: NCT00937144     History of Changes
Other Study ID Numbers: SCA123-CTIL 
Study First Received: September 24, 2008
Last Updated: February 28, 2010
Health Authority: Israel: Ministry of Health

Keywords provided by The Baruch Padeh Medical Center, Poriya:
endothelial function
endothelial progenitor stem cells

Additional relevant MeSH terms:
Anemia, Sickle Cell
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Genetic Diseases, Inborn
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents processed this record on December 07, 2016